Fin Trust Capital Advisors, LLC Immuno Gen, Inc. Transaction History

Fin Trust Capital Advisors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$4.75 - $7.5 $1,691 - $2,670	-356 Closed	0 $0
Q2 2020 Sep 11, 2020	BUY	$3.32 - $5.34 $1,181 - $1,901	356 New	356 $2,000
Q2 2020 Aug 14, 2020	SELL	$3.32 - $5.34 $2,466 - $3,967	-743 Closed	0 $0
Q4 2018 Feb 11, 2019	BUY	$3.94 - $9.7 $2,927 - $7,207	743 New	743 $4,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Fin Trust Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Fin Trust Capital Advisors, LLC with notifications on news.